Immuron Travelan highest sales in history Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in history March 2025 Quarter AUD$1.3 million up 2% on prior year Mar

Immuron Travelan highest sales in history

Sales Highlights (unaudited):

Melbourne, Australia, April 10, 2025: Immuron

Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued

sales growth (unaudited) of Travelan , an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they

produce in the gastrointestinal (GI) tract.

Flavio Palumbo, Chief Commercial Officer said

"For the first time, Immuron has exceeded A$5 million in sales - our highest fiscal year sales ever! That is with a quarter to come.

This is a fantastic result, with record sales quarter in December for Australia on the back of our travel activation program and importantly

our North American business continues to produce record results ahead of the key spring summer travel period. Overall year to date sales

globally is up 46% on last year. The December quarter was a record with Australian pharmacy wholesalers stocking up on the back of Immuron's

expanded pharmacy banner group agreements and ahead of the peak Christmas, New Year holiday period. Wholesaler stocking impacted Australia

quarterly sales to wholesalers. It did not impact ex-Wholesaler sales to pharmacies which continue to be strong. We continue to strengthen

our consumer and trade program that has seen Travelan ranked #1 by market share change, #2 by SKU and #3 by brand in the Anti-diarrheal

category (IQVIA Australian Pharmacy Scan - 4 weeks to March 2025). We are on track for another record year in Australia. We have

achieved record sales in both USA and Canada. The USA we continue to break record sales via our redefined direct to consumer marketing

approach. In Canada we have also achieved record sales with step one of our re-launch - achieving listings in major retailers. With strong

sales anticipated over the Easter, ANZAC holiday periods and spring, summer break in North America, we have great momentum to build further

on this record-breaking year."

has been authorised by the directors of Immuron Limited.

Chief Executive Officer

orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers' diarrhea, a

digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan is a purified

tablet preparation of hyper-immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria

and prevent colonization and the pathology associated with traveler's diarrhea. In Australia, Travelan is a listed medicine

on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Traveler's Diarrhea, reduce

the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan is a licensed natural health product (NPN

80046016) and is indicated to reduce the risk of Traveler's Diarrhea. In the U.S., Travelan is sold as a dietary supplement

for digestive tract protection.

About Traveler's diarrhea

is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating,

and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant

Immuron Limited (ASX:

IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal

antibodies for the treatment of inflammatory mediated and infectious diseases.

For more information

visit: https://www.immuron.com.au

FORWARD-LOOKING STATEMENTS:

This press release may contain "forward-looking

statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,

each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development

programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations

and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock

value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth

strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the

results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties

relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key

personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and

intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation

or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change

in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by